Online inquiry

IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8310MR)

This product GTTS-WQ8310MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets GLP1R gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002062.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2740
UniProt ID P43220
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ8310MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11948MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ7450MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GBR500
GTTS-WQ9481MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IPH-5401
GTTS-WQ3788MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ13308MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-06741086
GTTS-WQ11213MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ8855MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ13610MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA R1450
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW